Research could help develop sophisticated treatments for Type I diabetes

New research that significantly improves our understanding of how insulin interacts with cells in the human body is published today.

The study could have major implications for the development of treatments for Type I diabetes.

By developing and analysing a range of super active insulins, scientists from the York Structural Biology Laboratory at the University of York have been able to identify common features that point to the likely molecular structure of human insulin when it is active in the body.

The research also offers new insight into how insulin binds to insulin receptors on cells.

The research was conducted with colleagues at the Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic, and is published in the journal Proceedings of the National Academy of Sciences.

Dr Marek Brzozowski, from the York Structural Biology Laboratory, said: "The structures of inactive forms of insulin and the insulin receptor are reasonably well known, but documenting how they interact has proven to be a considerable scientific challenge.

"Improving our understanding of this interaction holds the key to developing far more sophisticated treatments for Type I diabetes and this research represents an important step forward."

The research could help the development of insulin treatments that can be more carefully controlled or that could be delivered without the need for injections.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Global diabetes cases exceed 800 million highlighting urgent need for action